Investigators performed a cluster-randomized, two-arm randomized clinical trial with schools as the unit of randomization to test the Superprotegidas behavioral intervention aimed at increasing HPV vaccination among girls and their caregivers. The trial followed the Phase III framework of the ORBIT Model for Behavioral Treatment Development, the authors reported. The intervention was explicitly built on the COM-B (Capability-Opportunity-Motivation-Behavior) theoretical framework. Components delivered to participants included a pedagogical workshop for girls, a letter sent to caregivers, an open chat (platform), multimedia messages, and parental reminders. The control condition and the exact content of usual care in control schools were not described in detail in the abstract.
A total of 77 girl–caregiver pairs enrolled in the trial, yielding 154 study participants. Girls were aged between 9 and 14 years. The study allocated 42 pairs to the intervention arm and 35 pairs to the control arm. The abstract provides these numbers but does not present further demographic breakdowns, such as socioeconomic status, urban versus rural school characteristics, or ethnicity, nor did it present details on cluster numbers per arm or on how many schools participated. The source did not report blinding procedures, allocation concealment mechanisms, or participant flow beyond enrollment counts in the abstract.
Post-intervention, vaccination uptake differed between arms. The intervention group achieved a vaccination rate of 52.4%, while the control group reached 28.6%. The authors reported an odds ratio of 2.75 with a 95% confidence interval of 1.06–7.12 for vaccination in the intervention versus control groups. Data indicated that receipt of the Superprotegidas program was associated with significantly higher odds of vaccination among age-eligible girls in this sample. The abstract does not specify exact timing of the post-intervention assessment relative to intervention delivery, nor does it report absolute numbers vaccinated in each arm beyond the percentages already given.
Beyond assignment to the intervention, the study team observed several predictors of increased vaccination uptake. Lower school level for the girl predicted higher uptake. Higher scores on multiple behavioral drivers framed within the COM-B model were also associated with vaccination. These specific drivers included: awareness of the vaccine's efficacy against cancer; awareness of vaccine safety; perceived availability of the vaccine in schools; reflective motivation focused on cancer prevention; and automatic motivation tied to perceived vaccine advantages. Higher caregiver self-efficacy was another independent predictor the authors noted. The abstract did not include the statistical models' full specifications, parameter estimates beyond the primary odds ratio, or whether interactions between predictors and intervention allocation were tested.
The authors reported that the Superprotegidas program was implemented using existing program resources in the municipality where the trial took place. The abstract indicates that this pragmatic approach aligns with potential scalability in similar school-based settings. The specific resource inputs, staff time, training requirements, fidelity measures, or cost estimates were not provided in the abstract. The delivery platforms (for example, the technical format of multimedia messages or the governance of the open chat) were described only at a high level; operational details were not included in the source abstract.
The abstract concludes that the intervention increased HPV vaccination rates among age-eligible girls in the enrolled cohort and suggested feasibility for broader implementation. The publication type lists this work as a randomized controlled trial and reports no conflicts of interest. Important methodological elements were not reported in the abstract: the number of clusters (schools) randomized, cluster sizes by school, methods used for random sequence generation and allocation concealment, whether outcome assessment was masked, the follow-up interval used to ascertain vaccination, and any monitoring of adverse events following vaccination. The abstract likewise did not supply detailed demographic tables, per-protocol versus intention-to-treat analyses, or economic analyses. These gaps mean readers must refer to the full text for comprehensive methods and secondary analyses.
The evidence presented in the abstract indicates that a school-based behavioral package—centered on the COM-B model and delivered through workshops, caregiver communication, and reminders—was associated with higher HPV vaccine uptake compared with control in this Colombian sample. Data reported in the abstract are limited to enrollment counts, age range, component descriptions, the primary vaccination percentages, the reported odds ratio with confidence interval, and a set of behavioral predictors. The abstract did not report adverse events, detailed operational costs, or the precise timing of outcome measurement; those items are not available in the source abstract and require consultation of the full manuscript for clarification.